Biosimilar Antibodies

MOR-8457 is a monoclonal antibody specifically designed to target PDGF-BB, a critical factor implicated in the pathogenesis of liver fibrosis. This antibody is optimized for use in murine models to investigate the molecular mechanisms and potential therapeutic targets for liver fibrosis.

Etalanetug is a humanized IgG1κ monoclonal antibody that selectively targets microtubule-associated protein tau (MAPT). For control experiments, it is recommended to use Human IgG1 kappa as the isotype control. This antibody is designed for the specific detection and study of MAPT's role in various biological processes, making it an essential tool for research in neurodegenerative diseases and other tauopathies.

The Anti-KLK5/Kallikrein 5 Antibody is a recombinant human antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the KLK5/Kallikrein 5 protease. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended.

Domvanalimab (AB154) is a humanized monoclonal antibody targeting TIGIT (T cell immunoreceptor with Ig and ITIM domains). This antibody selectively binds to human TIGIT, effectively inhibiting the interaction between TIGIT and its ligand CD155. Domvanalimab is primarily utilized in oncological research to explore the modulation of immune responses against cancer cells. This inhibition potentially enhances T cell activation and NK cell cytotoxicity, offering a promising avenue for cancer immunotherapy studies.

Ligufalimab (AK 117) is a humanized IgG4 monoclonal antibody targeting CD47. This antibody is engineered to avoid the induction of red blood cell (RBC) hemaglutination, while effectively promoting phagocytosis. Ligufalimab has demonstrated significant anti-tumor activity in various models, making it a valuable tool for research in cancer immunotherapy.

Gimsilumab (MORAb-022) is a human monoclonal antibody that targets granulocyte-macrophage colony-stimulating factor (GM-CSF). This antibody exhibits potential for use in research focused on COVID-19 and rheumatoid arthritis (RA), providing a valuable tool for investigating the role of GM-CSF in inflammation and immune response associated with these conditions.

Nivisnebart is a human monoclonal antibody of the IgG1κ subtype that specifically targets SORT1. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Serclutamab is a humanized chimeric monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), subclass IgG1-κ. It is produced in Chinese Hamster Ovary (CHO) cells, ensuring high fidelity and stability in its structure. This antibody is designed for use in research studies focused on the biological pathways influenced by EGFR, including cellular proliferation, differentiation, and survival.

Epcoritamab (GEN3013) is a bispecific IgG1 antibody designed to redirect T-cells to target CD3×CD20+ tumor cells. This antibody facilitates potent T-cell-mediated cytotoxicity against B-cell non-Hodgkin lymphoma (NHL) cell lines, offering a targeted approach to cancer immunotherapy.

MDX-1105 is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target B7-H1/PD-L1/CD274, a protein implicated in the negative regulation of immune responses. This antibody features a human IgG4SP subtype heavy chain and has a predicted molecular weight of approximately 150 kDa. For experimental control purposes, Human IgG4 kappa, Isotype Control serves as the appropriate isotype control for MDX-1105, ensuring accurate interpretation of results in research applications focused on immunomodulation and cancer immunotherapy.

Pimurutamab is a humanized IgG1-κ monoclonal antibody specifically designed to target the Epidermal Growth Factor Receptor (EGFR). This antibody is produced in CHO-K1 cells, ensuring high fidelity and consistency in performance. Pimurutamab binds to EGFR with high specificity, making it an invaluable tool for research focused on cancer biology and therapeutic development where EGFR plays a critical role.

Dresbuxelimab (AK-119) is an IgG-κ monoclonal antibody specifically designed to target CD73. It is produced using a Chinese Hamster Ovary (CHO) cell expression system. This antibody has potential applications in research focused on the enzymatic activity of CD73 and its role in immunosuppressive pathways, making it a valuable tool for studies in immunology and cancer research.

Icrucumab (IMC-18F1) is a human IgG1 monoclonal antibody that targets VEGFR-1 (FLT1). This antibody exhibits potential utility in the research of advanced solid tumors, providing a critical tool for investigating the role of VEGFR-1 in tumor angiogenesis and progression.

The Anti-ACVR2B Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target the ACVR2B receptor. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 144.42 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This antibody is suitable for a range of research applications focusing on the biological functions and pathophysiological roles of the ACVR2B receptor.

Lumretuzumab is a humanized monoclonal antibody that targets the human epidermal growth factor receptor 3 (HER3 or ERBB3). This recombinant antibody is designed for use in cancer research, facilitating the study of HER3's role in oncogenic signaling pathways and tumor progression. Lumretuzumab's specificity for HER3 makes it a valuable tool for investigating potential therapeutic interventions in HER3-associated malignancies.

Cendakimab (RPC4046; ABT 308; CC-93538) is a humanized, recombinant monoclonal antibody engineered to selectively target the interleukin-13 (IL-13) cytokine. Demonstrating high affinity and potency, this antibody effectively binds to both the wild-type and variant forms of human IL-13. Cendakimab inhibits the interaction of IL-13 with its receptors, IL-13Rα1 and IL-13Rα2, exhibiting half-maximal inhibitory concentrations (IC50s) of 352 pM and 631 pM, respectively, as determined by enzyme-linked immunosorbent assay (ELISA). Furthermore, it exhibits binding affinities of 52 pM for wild-type IL-13 and 50 pM for the R110Q polymorphic variant of IL-13. The therapeutic potential of Cendakimab spans various IL-13-mediated allergic and inflammatory conditions, including asthma and eosinophilic esophagitis.

DX-2647 is a human monoclonal antibody that targets insulin-like growth factor-II (IGF-II), exhibiting potent anti-tumor and anti-proliferative properties. This antibody is specifically designed to bind to IGF-II, thereby inhibiting its interaction with the insulin-like growth factor 1 receptor (IGF-1R) and the insulin receptor (IR), which are critical pathways in cancer cell proliferation and survival. DX-2647 offers a promising therapeutic strategy for the treatment of cancers characterized by elevated levels of IGF-II.

Anti-IL-9 Antibody (MH9A4) is a mouse monoclonal antibody of the IgG2b, κ subclass, specifically designed to target human interleukin-9 (IL-9). This chimeric antibody is engineered for high specificity and affinity in recognizing and binding to IL-9, a cytokine involved in various inflammatory and immune responses. For appropriate experimental controls, it is recommended to use Mouse IgG2b kappa, Isotype Control, which serves as a non-reactive isotype control to help distinguish specific from non-specific binding.

Muromonab is a monoclonal antibody that specifically targets the CD3 receptor on T cells. This antibody effectively blocks cytotoxic T cell activity, serving as a potent immunosuppressive agent. It is primarily used to prevent acute rejection in solid organ transplantation by inhibiting the immune response that can lead to organ rejection.

Milatuzumab (hLL1; MEDI-115) is a humanized monoclonal antibody targeting CD74, an integral membrane protein implicated in the promotion of B-cell growth and survival. This antibody induces the generation of reactive oxygen species and disrupts mitochondrial membrane potential, leading to apoptosis. Additionally, Milatuzumab reduces CD20/CD74 aggregates and cell adhesion, further promoting cell death. This antibody is pivotal for research into the mechanisms of B-cell malignancies and autoimmune diseases, where CD74 plays a key role.

Vatelizumab (GBR500) is a monoclonal antibody specifically designed to target the α2 subunit (CD49b) of very late antigen-2 (VLA-2). This antibody is primarily utilized in the investigation of multiple sclerosis, offering a valuable tool for researchers studying the pathogenesis and potential treatments of this neurological disorder.

The Anti-CD9 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the CD9 antigen. This antibody comprises human IgG2 heavy chains and human lambda light chains, with an approximate molecular weight of 145.98 kDa. For isotype control, Human IgG1 kappa, Isotype Control is recommended. This product is ideal for research applications focusing on the role of CD9 in cellular processes and disease mechanisms.

Diridavumab is a monoclonal antibody targeting the HA stalk of the influenza virus. It functions by stabilizing the prefusion conformation of hemagglutinin (HA) and inhibiting the pH-dependent fusion of cellular and viral membranes within endosomes. This antibody is specifically utilized in research focused on the H2 subtype of the influenza virus, providing a valuable tool for studies aimed at understanding viral entry mechanisms and developing therapeutic strategies.

Unasnemab (MT-3921), a humanized IgG1 monoclonal antibody, specifically targets and binds to repulsive guidance molecule A (RGMa). This interaction facilitates the improvement of locomotor functions and promotes neuroregeneration. Unasnemab is primarily utilized in research focused on spinal cord injuries, offering significant insights into therapeutic strategies and recovery mechanisms.

Sulesomab (IMMU-MN3) is a murine monoclonal antibody fragment belonging to the IgG1 class, specifically designed to target Normal Cross-Reactive Antigen-90 (NCA-90) found on leukocytes. This antibody demonstrates enhanced localization to sites of infection, facilitated by its ability to exploit the increased permeability of capillary membranes associated with inflammatory responses. Sulesomab is utilized primarily in research focused on the identification and characterization of leukocyte dynamics during infection and inflammatory processes.

Magrolimab (Hu5F9-G4) is a humanized monoclonal antibody targeting CD47. By inhibiting the CD47-mediated "don't eat me" signal, Magrolimab enhances macrophage-mediated phagocytosis. This antibody demonstrates significant antitumor activity, particularly in the treatment of malignant bone tumors and breast cancer, making it a valuable tool for research in oncology and immunotherapy.

Anti-TCR (NKTT320) is a novel humanized monoclonal antibody that specifically targets the invariant T cell receptor (TCR). This antibody is designed for use in cell-based cancer immunotherapy, offering a targeted approach to modulate the immune system's response against cancerous cells.

PY159 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting TREM1 (Triggering Receptor Expressed on Myeloid cells 1), also known as CD354. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 143.66 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Opelkibart is a human IgG1 κ monoclonal antibody targeting the KIT receptor. For control experiments, it is recommended to use Human IgG1 kappa as an isotype control.

Nelmastobart is a human IgG4 κ monoclonal antibody targeting BTN1A1. For accurate experimental controls, it is recommended to use Human IgG4 (S228P) kappa as an isotype control.

Negalstobart is a human IgG4 κ monoclonal antibody targeting LAG-3. For control experiments, it is recommended to use Human IgG4 (S228P) kappa as an isotype control.

Anti-PAR2 is a monoclonal antibody specifically targeting Protease-Activated Receptor 2 (PAR2). This receptor is a key player in various biological processes, including inflammation and pain perception, making this antibody an essential tool for research in these areas. It is designed for use in a range of applications such as Western blotting, immunohistochemistry, and flow cytometry, providing researchers with a reliable means to study PAR2 expression and function in different biological contexts.

Anti-TYRO3 (ELB031) is a monoclonal antibody specifically designed to target and bind to the TYRO3 and MERTK receptors. This antibody is produced for the purpose of studying the signaling pathways and biological functions associated with these receptor tyrosine kinases, which are implicated in various cellular processes including cell survival, migration, and differentiation. Anti-TYRO3 (ELB031) is ideal for use in research applications focused on cancer, immune regulation, and neurological diseases where TYRO3 and MERTK play critical roles.

M6903 is a humanized monoclonal IgG2 antibody that specifically targets T cell immunoglobulin and mucin domain-3 (TIM-3), exhibiting a dissociation constant (K_D) of 2.3 nM for human TIM-3. This antibody effectively binds to TIM-3, inhibiting its interaction with key ligands including phosphatidylserine (PtdSer), carcinoembryonic antigen cell adhesion-related molecule 1 (CEACAM1), and galectin 9 (Gal-9). By blocking these interactions, M6903 mitigates TIM-3-mediated suppression of T cell activity, thereby activating antigen-specific T cells and enhancing anti-tumor immune responses. This antibody is particularly valuable for research focused on cancer immunology and the development of immunotherapeutic strategies.

Obiltoxaximab (ETI 204) is a highly potent monoclonal antibody targeting the protective antigen (PA) component of Bacillus anthracis, the bacterium responsible for anthrax. This antibody is critical in disrupting the assembly of anthrax toxin, thereby preventing the intoxication of target cells. Demonstrating efficacy in animal models, Obiltoxaximab enhances survival rates and impedes the peripheral dissemination of the bacteria. It is primarily utilized in research focused on inhalational anthrax, as well as associated bacteremia and toxemia. This makes Obiltoxaximab an essential tool for studies aimed at understanding and mitigating the pathogenic mechanisms of anthrax.

Becotatug (JMT-101) is an IgG1 monoclonal antibody specifically designed to target the Epidermal Growth Factor Receptor (EGFR). This antibody can be conjugated with Afatinib and Osimertinib, enabling its use as a synthetic antibody-drug conjugate (ADC) for targeted cancer therapy. This feature allows for the precise delivery of therapeutic agents to EGFR-expressing cells, potentially enhancing treatment efficacy and reducing off-target effects.

Acrixolimab is a humanized IgG4-κ monoclonal antibody designed to selectively target PD-1 (Programmed Death-1). This antibody is engineered to bind with high specificity to the PD-1 receptor, thereby modulating immune responses and enhancing immune cell activity. Acrixolimab is primarily used in research focused on immunotherapy and the study of immune checkpoint pathways in oncology.

The Anti-TGFb1 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Transforming Growth Factor Beta 1 (TGFb1). This antibody comprises a human IgG1 type heavy chain and a human kappa type light chain, with an approximate molecular weight of 145 kDa. For isotype control, Human IgG1 kappa, Isotype Control is recommended. This product is ideal for research applications focusing on the biological activities and regulatory mechanisms of TGFb1.

Rinatabart is a human monoclonal antibody of the IgG1κ subtype designed to target FOLR1. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control. This specificity makes Rinatabart suitable for research focused on the biological pathways and diseases associated with the FOLR1 receptor.

Cepeprubart is a human IgG2 κ monoclonal antibody specifically targeting SELPLG. For accurate experimental control, it is recommended to use Human IgG2 kappa as an isotype control.

Modotuximab (DS 1024) is a chimeric monoclonal antibody of the IgG1κ isotype, designed to specifically target the human Epidermal Growth Factor Receptor (EGFR). This antibody recognizes non-overlapping epitopes located on domain III of the EGFR protein, a region preserved in the EGFR variant III (EGFRvIII). Modotuximab demonstrates potent antitumor activity in vivo, making it a valuable tool for research in cancer biology and therapeutic development.

Anti-YB-1 Antibody (21A3) is a chimeric mouse IgG1 monoclonal antibody specifically designed to target human Y-box binding protein 1 (YB-1). For accurate experimental control, it is recommended to use Mouse IgG1 kappa Isotype Control alongside this antibody.

Rolinsatamab is a chimeric monoclonal antibody of the IgG1κ subtype, specifically designed to target the prolactin receptor (PRLR). This antibody can be conjugated to the pyrrolobenzodiazepine (PDB) dimer SGD-1882 through a cleavable maleimidocaproyl linker, creating the antibody-drug conjugate known as Rolinsatamab talirine. This conjugate features an average of two site-specific drug attachments at engineered cysteines (S239C). The linker incorporates a valine-alanine dipeptide, which serves as a cleavage site for cathepsin B, facilitating the release of the cytotoxic agent upon entry into targeted cells. Rolinsatamab talirine is primarily utilized in therapeutic applications where precise delivery of cytotoxic agents to cells expressing PRLR is required.

The Anti-CDH1/E-cadherin/CD324 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It is designed to specifically target CDH1, also known as E-cadherin or CD324, a critical protein involved in cell-cell adhesion and cancer metastasis regulation. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 146.6 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended. This antibody is applicable for use in various immunodetection techniques to study E-cadherin expression in pathological samples or in research focused on epithelial cell biology and oncology.

Sotigalimab is a CD40 agonistic monoclonal antibody designed to selectively bind to CD40 with high affinity. This interaction promotes the activation of antigen-presenting cells, which in turn enhances cancer-specific T cell responses. Primarily utilized in research focused on metastatic pancreatic cancer and metastatic melanoma, Sotigalimab serves as a critical tool in the investigation of immune-mediated therapies targeting these aggressive cancers.

The Anti-TREM2 Antibody (AL2p-58) is a humanized IgG1 monoclonal antibody specifically designed to target TREM2, a receptor expressed on microglia and involved in the regulation of inflammatory processes. For accurate experimental control, it is recommended to use Human IgG1 kappa as an isotype control. This antibody is ideal for research applications investigating the role of TREM2 in neuroinflammation and other related pathological conditions.

Abituzumab (DI17E6) is a humanized monoclonal antibody of the IgG2 subtype that targets integrin αV. It effectively inhibits the phosphorylation of focal adhesion kinase (FAK), Akt, and extracellular signal-regulated kinase (ERK), key signaling molecules involved in cell migration and survival. This antibody is particularly useful in cancer research applications, with a focus on studies related to prostate cancer. Abituzumab's precise targeting of integrin αV makes it a valuable tool for investigating the role of this integrin in tumor progression and metastasis.

Lacutamab (IPH4102) is a recombinantly produced humanized monoclonal antibody targeting the immune receptor KIR3DL2. Manufactured in Chinese Hamster Ovary (CHO) cells, this antibody is specifically designed for research applications focusing on cutaneous T-cell lymphoma. Lacutamab's precise specificity for KIR3DL2 makes it a valuable tool in the study of immune interactions and therapeutic responses in this lymphoma subtype.

Donitabart is a chimeric humanized antibody of the IgG1κ subtype that specifically targets ganglioside GD2. For experimental control purposes, the recommended isotype control is Human IgG1 kappa.